Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068864 | 0.84 | CYP2C19 (0.44) | KDM4EEPHX1EPHX2RETCYP2D6 | |
| SCHEMBL20147679 | 0.83 | EPHX1 (0.37) | KDM4EEPHX1EPHX2RETCYP2D6 | |
| SCHEMBL21651968 | 0.78 | KDM4E (0.49) | KDM4EEPHX1RETCYP2D6CYP2C19 | |
| SCHEMBL20068982 | 0.75 | KDM4E (0.44) | KDM4EEPHX1EPHX2RETCYP2D6 | |
| SCHEMBL16306650 | 0.75 | DRD2 (0.46) | KDM4EEPHX1EPHX2POLBMMP1 | |
| SCHEMBL20147677 | 0.74 | RET (0.43) | KDM4EEPHX1EPHX2RETTP53 | |
| SCHEMBL22857037 | 0.74 | RET (0.37) | KDM4EEPHX1EPHX2RETCYP2D6 | |
| SCHEMBL20147974 | 0.74 | CYP2D6 (0.41) | KDM4EEPHX1EPHX2CYP2D6MMP1 | |
| SCHEMBL13423615 | 0.72 | CYP2D6 (0.45) | KDM4EEPHX1EPHX2CYP2D6CYP2C19 | |
| SCHEMBL18389973 | 0.69 | KDM4E (0.65) | KDM4ECYP2D6CYP2C19HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | KDM4E 547/4885EPHX1 1481/4885EPHX2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.